289 related articles for article (PubMed ID: 35704974)
1. Up-front cell-free DNA next generation sequencing improves target identification in UK first line advanced non-small cell lung cancer (NSCLC) patients.
Cui W; Milner-Watts C; O'Sullivan H; Lyons H; Minchom A; Bhosle J; Davidson M; Yousaf N; Scott S; Faull I; Kushnir M; Nagy R; O'Brien M; Popat S
Eur J Cancer; 2022 Aug; 171():44-54. PubMed ID: 35704974
[TBL] [Abstract][Full Text] [Related]
2. Clinical utility of a plasma-based comprehensive genomic profiling test in patients with non-small cell lung cancer in Korea.
Ahn BC; Lee S; Lee J; Lee JB; Hong MH; Lim SM; Jain S; Olsen S; Cho BC
Cancer Treat Res Commun; 2023; 36():100715. PubMed ID: 37307681
[TBL] [Abstract][Full Text] [Related]
3. A pilot of Blood-First diagnostic cell free DNA (cfDNA) next generation sequencing (NGS) in patients with suspected advanced lung cancer.
Cui W; Milner-Watts C; McVeigh TP; Minchom A; Bholse J; Davidson M; Yousaf N; MacMahon S; Mugalaasi H; Gunapala R; Lee R; George A; Popat S; O'Brien M
Lung Cancer; 2022 Mar; 165():34-42. PubMed ID: 35085982
[TBL] [Abstract][Full Text] [Related]
4. Biomarker Discovery and Outcomes for Comprehensive Cell-Free Circulating Tumor DNA Versus Standard-of-Care Tissue Testing in Advanced Non-Small-Cell Lung Cancer.
Palmero R; Taus A; Viteri S; Majem M; Carcereny E; Garde-Noguera J; Felip E; Nadal E; Malfettone A; Sampayo M; Riva F; Nagy RJ; Lanman RB; Faull I; Dix D; Karachaliou N; Rosell R
JCO Precis Oncol; 2021 Nov; 5():93-102. PubMed ID: 34994593
[TBL] [Abstract][Full Text] [Related]
5. Plasma cfDNA Genotyping in Hospitalized Patients With Suspected Metastatic NSCLC.
Cheng ML; Milan MSD; Tamen RM; Bertram AA; Michael KS; Ricciuti B; Kehl KL; Awad MM; Sholl LM; Paweletz CP; Jänne PA
JCO Precis Oncol; 2021 Nov; 5():726-732. PubMed ID: 34994618
[TBL] [Abstract][Full Text] [Related]
6. Heterogeneous mutation pattern in tumor tissue and circulating tumor DNA warrants parallel NGS panel testing.
Guo Q; Wang J; Xiao J; Wang L; Hu X; Yu W; Song G; Lou J; Chen J
Mol Cancer; 2018 Aug; 17(1):131. PubMed ID: 30153823
[TBL] [Abstract][Full Text] [Related]
7. Treatment of Non-Small-Cell Lung Cancer Based on Circulating Cell-Free DNA and Impact of Variation Allele Frequency.
Bustamante Alvarez JG; Janse S; Owen DH; Kiourtsis S; Bertino EM; He K; Carbone DP; Otterson GA
Clin Lung Cancer; 2021 Jul; 22(4):e519-e527. PubMed ID: 33414052
[TBL] [Abstract][Full Text] [Related]
8. High concordance of actionable genomic alterations identified between circulating tumor DNA-based and tissue-based next-generation sequencing testing in advanced non-small cell lung cancer: The Korean Lung Liquid Versus Invasive Biopsy Program.
Park S; Olsen S; Ku BM; Lee MS; Jung HA; Sun JM; Lee SH; Ahn JS; Park K; Choi YL; Ahn MJ
Cancer; 2021 Aug; 127(16):3019-3028. PubMed ID: 33826761
[TBL] [Abstract][Full Text] [Related]
9. Next-generation sequencing for tumor mutation quantification using liquid biopsies.
Provencio M; Pérez-Barrios C; Barquin M; Calvo V; Franco F; Sánchez E; Sánchez R; Marsden D; Cristóbal Sánchez J; Martin Acosta P; Laza-Briviesca R; Cruz-Bermúdez A; Romero A
Clin Chem Lab Med; 2020 Jan; 58(2):306-313. PubMed ID: 31469650
[TBL] [Abstract][Full Text] [Related]
10. Differences in the genomic profiles of cell-free DNA between plasma, sputum, urine, and tumor tissue in advanced NSCLC.
Wu Z; Yang Z; Li CS; Zhao W; Liang ZX; Dai Y; Zhu Q; Miao KL; Cui DH; Chen LA
Cancer Med; 2019 Mar; 8(3):910-919. PubMed ID: 30767431
[TBL] [Abstract][Full Text] [Related]
11. Clinical Outcomes for Plasma-Based Comprehensive Genomic Profiling Versus Standard-of-Care Tissue Testing in Advanced Non-Small Cell Lung Cancer.
Page RD; Drusbosky LM; Dada H; Raymond VM; Daniel DB; Divers SG; Reckamp KL; Villalona-Calero MA; Dix D; Odegaard JI; Lanman RB; Papadimitrakopoulou VA; Leighl NB
Clin Lung Cancer; 2022 Jan; 23(1):72-81. PubMed ID: 34782240
[TBL] [Abstract][Full Text] [Related]
12. Use of capture-based next-generation sequencing to detect ALK fusion in plasma cell-free DNA of patients with non-small-cell lung cancer.
Cui S; Zhang W; Xiong L; Pan F; Niu Y; Chu T; Wang H; Zhao Y; Jiang L
Oncotarget; 2017 Jan; 8(2):2771-2780. PubMed ID: 27926526
[TBL] [Abstract][Full Text] [Related]
13. Plasma Cell-Free DNA Genotyping: From an Emerging Concept to a Standard-of-Care Tool in Metastatic Non-Small Cell Lung Cancer.
Gray J; Thompson JC; Carpenter EL; Elkhouly E; Aggarwal C
Oncologist; 2021 Oct; 26(10):e1812-e1821. PubMed ID: 34216176
[TBL] [Abstract][Full Text] [Related]
14. Detection of ubiquitous and heterogeneous mutations in cell-free DNA from patients with early-stage non-small-cell lung cancer.
Jamal-Hanjani M; Wilson GA; Horswell S; Mitter R; Sakarya O; Constantin T; Salari R; Kirkizlar E; Sigurjonsson S; Pelham R; Kareht S; Zimmermann B; Swanton C
Ann Oncol; 2016 May; 27(5):862-7. PubMed ID: 26823523
[TBL] [Abstract][Full Text] [Related]
15. Amplicon-based next-generation sequencing of plasma cell-free DNA for detection of driver and resistance mutations in advanced non-small cell lung cancer.
Guibert N; Hu Y; Feeney N; Kuang Y; Plagnol V; Jones G; Howarth K; Beeler JF; Paweletz CP; Oxnard GR
Ann Oncol; 2018 Apr; 29(4):1049-1055. PubMed ID: 29325035
[TBL] [Abstract][Full Text] [Related]
16. Clinical Impact of Plasma and Tissue Next-Generation Sequencing in Advanced Non-Small Cell Lung Cancer: A Real-World Experience.
Bonanno L; Pavan A; Ferro A; Calvetti L; Frega S; Pasello G; Aprile G; Guarneri V; Conte P;
Oncologist; 2020 Dec; 25(12):e1996-e2005. PubMed ID: 32557976
[TBL] [Abstract][Full Text] [Related]
17. Development of a gene panel for next-generation sequencing of clinically relevant mutations in cell-free DNA from cancer patients.
Malapelle U; Mayo de-Las-Casas C; Rocco D; Garzon M; Pisapia P; Jordana-Ariza N; Russo M; Sgariglia R; De Luca C; Pepe F; Martinez-Bueno A; Morales-Espinosa D; González-Cao M; Karachaliou N; Viteri Ramirez S; Bellevicine C; Molina-Vila MA; Rosell R; Troncone G
Br J Cancer; 2017 Mar; 116(6):802-810. PubMed ID: 28170370
[TBL] [Abstract][Full Text] [Related]
18. Development and clinical validation of a circulating tumor DNA test for the identification of clinically actionable mutations in nonsmall cell lung cancer.
Liu L; Liu H; Shao D; Liu Z; Wang J; Deng Q; Tang H; Yang H; Zhang Y; Qiu Y; Cui F; Tan M; Zhang P; Li Z; Liu J; Liang W; Wang Y; Peng Z; Wang J; Yang H; Mao M; Kristiansen K; Ye M; He J
Genes Chromosomes Cancer; 2018 Apr; 57(4):211-220. PubMed ID: 29277949
[TBL] [Abstract][Full Text] [Related]
19. Longitudinal Shifts of Solid Tumor and Liquid Biopsy Sequencing Concordance in Metastatic Breast Cancer.
Liu MC; MacKay M; Kase M; Piwowarczyk A; Lo C; Schaeffer J; Finkle JD; Mason CE; Beaubier N; Blackwell KL; Park BH
JCO Precis Oncol; 2022 Jun; 6(1):e2100321. PubMed ID: 35721584
[TBL] [Abstract][Full Text] [Related]
20. Genetic Profiling of Cell-Free DNA From Pleural Effusion in Advanced Lung Cancer as a Surrogate for Tumor Tissue and Revealed Additional Clinical Actionable Targets.
Tu HY; Li YS; Bai XY; Sun YL; Zheng MY; Ke EE; Liao RQ; Jiang BY; Lin JX; Huang J; Xu BF; Yang JJ; Zhang XC; Zhou Q; Wang BC; Chen HJ; Tong X; Yu R; Wu X; Zhu D; Wu YL
Clin Lung Cancer; 2022 Mar; 23(2):135-142. PubMed ID: 34645582
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
